Indevus Announces Clinical and Regulatory Plans for Pagoclone
Company to Move Forward in Phase III Trials in Stuttering
Future Work on Premature Ejaculation Not Planned After Interim Analysis of Phase II Trial Showed Insufficient Efficacy
LEXINGTON, Mass.--Indevus Pharmaceuticals today announced that following an End of Phase II meeting with the FDA, the Company has established a clinical plan towards regulatory approval of pagoclone for the treatment of persistent developmental stuttering (PDS) and will initiate a Phase III trial in the first half of 2007. Separately, following an interim analysis of the Company’s Phase II trial of pagoclone in premature ejaculation (PE), the Company has chosen to discontinue the trial due to insufficient efficacy.
See more here.
4 comments:
Merci fir dësen Blog! Als Concernéierten (obwuel et vill manner schlemm ass wéi fréier) verfollegen ech die néisten Erkenntnisser a Punkto Tuddelen mat groussem Interesse.
Sollten miir eis net emmer eng Keier treffen? check miir eng SMS op den 621 432263.
Note: This is Luxembourgish!
ok, hun der eng sms gescheckt. dann maan mer demnächst en RDV aus. cya!
Hey,hey...
Nach en Tuddler am Laendchen!
Do muss ech awer och matt vun der Partie sinn... Dann sot mer Bescheed wann der een drenken gidd, bis dann, Einar
Post a Comment